Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.
暂无分享,去创建一个
M. Vogeser | M. Schwaiblmair | P. Cremer | W. Scheidt | J. Koglin | J Koglin | S Pehlivanli | M Schwaiblmair | M Vogeser | P Cremer | W vonScheidt | S. Pehlivanli | W. vonScheidt | M. Schwaiblmair
[1] C. Vogelmeier,et al. Lung function and cardiopulmonary exercise performance after heart transplantation: influence of cardiac allograft vasculopathy. , 1999, Chest.
[2] J. Cohn,et al. Prognosis of congestive heart failure and predictors of mortality. , 1988, The American journal of cardiology.
[3] W. Edwards,et al. Natriuretic peptide system in human heart failure. , 1993, Circulation.
[4] P. Poole‐Wilson,et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.
[5] N. Reichek,et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[6] K. Kugiyama,et al. Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.
[7] W. Abraham,et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. , 1998, Journal of cardiac failure.
[8] A. Richards,et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea , 1994, The Lancet.
[9] K. Bailey,et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. , 1996, Hypertension.
[10] S. Anker,et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. , 1997, Circulation.
[11] M. Radford,et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. , 1996, Circulation.
[12] N. Kennedy,et al. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. , 1996, The American journal of cardiology.
[13] C. Lang,et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. , 1996, The American journal of cardiology.
[14] J R Wilson,et al. Value of Peak Exercise Oxygen Consumption for Optimal Timing of Cardiac Transplantation in Ambulatory Patients With Heart Failure , 1991, Circulation.
[15] J. Schroeder,et al. Analysis of deaths in patients awaiting heart transplantation: impact on patient selection criteria. , 1996, Heart.
[16] Orton,et al. INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .
[17] H. Tunstall-Pedoe,et al. Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.
[18] R. T. Lie,et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.
[19] J. Cohn. Prognostic factors in heart failure: Poverty amidst a wealth of variables , 1989 .
[20] R. Doughty,et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 1999, Circulation.
[21] T. Omland,et al. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. , 1996, Heart.
[22] B. Pitt,et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. , 1989, Journal of the American College of Cardiology.
[23] R. Shabetai,et al. Prediction of outcome in late-stage cardiomyopathy. , 1990, American heart journal.
[24] D. Gardner,et al. N ATRIURETIC P EPTIDES , 1998 .
[25] D. Heitjan,et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. , 1996, Circulation.
[26] J Keegan,et al. Predictors of prognosis in severe chronic heart failure. , 1992, American heart journal.
[27] D. Fukai,et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.
[28] W. Abraham,et al. Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.
[29] F. Tristani,et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .
[30] J. Schwartz,et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.